Fig. 7: PACpAInt identification of intra-heterogeneity-based PDAC subtypes.

a Patient distribution in four subtypes: main-classical, intermediary, hybrid, and main basal-like. For each column-wise patient is first shown the 99th percentile basal-like and classical scores and second the proportion of tumor tiles for different levels of basal-like and classical phenotype, b Schematic illustration of the intra-tumoral distribution of tumor cell phenotypes along a basal-like vs classical differentiation axis, c Distribution of the tumor-level RNA-defined signature scores of the basal-like and classical phenotypes compared between the four subtypes: main classical, intermediate, hybrid, and main basal-like, (n = 451 in total, high.bas n = 84, high.cla n = 192, hybrid n = 45, inter n = 130). Center corresponds to the median, lower and upper hingers to the first and third quartiles, whiskers to the hist/lowest value no further than 1.5 × IQR, d Kaplan–Meier analysis of disease-free and overall survival comparing main classical, intermediate, hybrid, and main basal-like tumor, e Distribution of PACpAInt-defined subtypes in a principal component analysis based on transcriptomic profiles of the tumors, f Differential enrichment by gene set variation analysis of pathways in PACpAInt-defined subtypes (n = 272 in total, high.bas n = 61, high.cla n = 128, inter n = 83). Center corresponds to the median, lower and upper hingers to the first and third quartiles, and whiskers to the hist/lowest value no further than 1.5 × IQR. Source data are provided as a Source Data file.